Articles > Regencell Bioscience Holdings Limited Faces Class Action Lawsuit Over Securities Fraud Allegations
- Rosen Law Firm reminds investors of lead plaintiff deadline in class action lawsuit against Regencell Bioscience Holdings Limited
- RGC Resources, Inc. reports second quarter earnings increase compared to previous year
- Glancy Prongay Wolke & Rotter LLP files securities fraud class action lawsuit against Regencell Bioscience Holdings Limited
- Bronstein, Gewirtz & Grossman LLC urges Regencell investors to take action regarding alleged securities fraud violations
- Faruqi & Faruqi, LLP reminds investors of June 23, 2026 deadline to seek lead plaintiff role in class action against Regencell
Regencell Bioscience Holdings Limited is facing a class action lawsuit after allegations of securities fraud. Rosen Law Firm, a global investor rights law firm, has reminded investors of the important June 23, 2026 lead plaintiff deadline for the case. Investors who purchased Regencell securities between October 28, 2024 and October 31, 2025 may be entitled to compensation without having to pay any out-of-pocket fees.
In a separate development, RGC Resources, Inc. announced an increase in consolidated company earnings in the second quarter ended March 31, 2026. The earnings rose to $8.7 million, or $0.84 per diluted share, compared to $7.7 million, or $0.74 per diluted share, in the same quarter of the previous year. The increase was attributed to higher operating margins and earnings from the company's investment in the Mountain Valley Pipeline, LLC.
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, has filed a securities fraud class action lawsuit against Regencell Bioscience Holdings Limited. The lawsuit covers investors who purchased or acquired Regencell securities between October 28, 2024 and October 31, 2025. The deadline for investors to file a lead plaintiff motion is June 23, 2026.
Additionally, Bronstein, Gewirtz & Grossman LLC is urging investors to take action regarding alleged securities fraud violations by Regencell. The class action lawsuit aims to help investors seek recovery for any harm suffered. The lead plaintiff deadline for this case is also June 23, 2026.
Faruqi & Faruqi, LLP is also reminding investors of the upcoming deadline to seek the role of lead plaintiff in the federal securities class action filed against Regencell. Investors who purchased or acquired securities in Regencell between October 28, 2024 and October 31, 2025 are encouraged to contact the firm to discuss their legal rights. The deadline for seeking the role of lead plaintiff is June 23, 2026.
In another development, Levi & Korsinsky, LLP has reminded purchasers of Regencell Bioscience Holdings Limited securities about a pending securities class action lawsuit. The lawsuit focuses on alleged misrepresentations regarding Regencell's $1 million research and development budget compared to its $14 billion market valuation. Investors who purchased Regencell securities between October 28, 2024 and October 31, 2025 may be eligible to participate in the lawsuit.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Regencell Bioscience Holdings Limited Faces Class Action Lawsuit Over Securities Fraud Allegations
By KlickAnalytics Data Insights | May 6, 2026 08:05PM ET
Key Points
- Rosen Law Firm reminds investors of lead plaintiff deadline in class action lawsuit against Regencell Bioscience Holdings Limited
- RGC Resources, Inc. reports second quarter earnings increase compared to previous year
- Glancy Prongay Wolke & Rotter LLP files securities fraud class action lawsuit against Regencell Bioscience Holdings Limited
- Bronstein, Gewirtz & Grossman LLC urges Regencell investors to take action regarding alleged securities fraud violations
- Faruqi & Faruqi, LLP reminds investors of June 23, 2026 deadline to seek lead plaintiff role in class action against Regencell
Regencell Bioscience Holdings Limited is facing a class action lawsuit after allegations of securities fraud. Rosen Law Firm, a global investor rights law firm, has reminded investors of the important June 23, 2026 lead plaintiff deadline for the case. Investors who purchased Regencell securities between October 28, 2024 and October 31, 2025 may be entitled to compensation without having to pay any out-of-pocket fees.
In a separate development, RGC Resources, Inc. announced an increase in consolidated company earnings in the second quarter ended March 31, 2026. The earnings rose to $8.7 million, or $0.84 per diluted share, compared to $7.7 million, or $0.74 per diluted share, in the same quarter of the previous year. The increase was attributed to higher operating margins and earnings from the company's investment in the Mountain Valley Pipeline, LLC.
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, has filed a securities fraud class action lawsuit against Regencell Bioscience Holdings Limited. The lawsuit covers investors who purchased or acquired Regencell securities between October 28, 2024 and October 31, 2025. The deadline for investors to file a lead plaintiff motion is June 23, 2026.
Additionally, Bronstein, Gewirtz & Grossman LLC is urging investors to take action regarding alleged securities fraud violations by Regencell. The class action lawsuit aims to help investors seek recovery for any harm suffered. The lead plaintiff deadline for this case is also June 23, 2026.
Faruqi & Faruqi, LLP is also reminding investors of the upcoming deadline to seek the role of lead plaintiff in the federal securities class action filed against Regencell. Investors who purchased or acquired securities in Regencell between October 28, 2024 and October 31, 2025 are encouraged to contact the firm to discuss their legal rights. The deadline for seeking the role of lead plaintiff is June 23, 2026.
In another development, Levi & Korsinsky, LLP has reminded purchasers of Regencell Bioscience Holdings Limited securities about a pending securities class action lawsuit. The lawsuit focuses on alleged misrepresentations regarding Regencell's $1 million research and development budget compared to its $14 billion market valuation. Investors who purchased Regencell securities between October 28, 2024 and October 31, 2025 may be eligible to participate in the lawsuit.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.